Biopharma industry veteran Jackie Elbonne, Ph.D., is retiring at the end of the year, leaving Amgen’s top quality spot to her ...
To Bill Sibold, “it’s hard to find a more attractive growth opportunity in biotech” than metabolic dysfunction-associated steatohepatitis (MASH). | To Madrigal CEO Bill Sibold, “it’s hard to find a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results